Aimmune Therapeutics (AIMT) PT Lowered to $74 at Wedbush, Maintains 'Outperform'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 10 | New: 4
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 10 | New: 4
Join SI Premium – FREE
Wedbush analyst Liana Moussatos lowered the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $74.00 (from $81.00) while maintaining a Outperform rating.
- XmAb7195 May Improve PALFORZIA Patient Success
- Nestle Strengthens Partnership
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zscaler (ZS) PT Raised to $235 at Mizuho
- Kepler Cheuvreux Upgrades Grand City Properties SA (GYC:GR) to Buy
- KeyBanc Upgrades Corteva Inc. (CTVA) to Overweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Liana MoussatosSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
